Goal
Development of a robust, reliable, and reproducible workflow solution for the analysis and quantitation of immunosuppressant drugs in blood for clinical research using triple quadrupole mass spectrometry coupled with ultra-high performing liquid chromatography.
Application benefits
- Development of a robust workflow for the analysis and quantitation of immunosuppressant drugs in blood with an ultra-high performing liquid chromatograph (UHPLC) and Thermo Scientific™ TSQ Fortis™ triple quadrupole mass spectrometer (QqQ)
- Leveraging enhanced performance of a robust QqQ with the sensitivity needed to develop a robust, reliable, reproducible quantitative workflow
Introduction
Starting with cyclosporine A, several immunosuppressant drugs have been developed and introduced, including the macrolides tacrolimus, sirolimus, and everolimus (Figure 1).
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
Thermo Fisher Scientific
168 3rd Ave
Waltham, MA USA 02451
Phone: 800-678-5599
www.thermofisher.com
>> Download the full Application Note as PDF
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
